Onxon Biopharma: Plans to buy back 25-49 million shares for equity incentive.

Sina Finance News on March 31, Anxu Biotech announced that the company plans to repurchase shares through centralized bidding trading method, with a total repurchase fund of 25 to 49 million yuan, funded from its own funds. The repurchase share price shall not exceed 41 yuan per share, with a quantity of 609,756 shares to 1,195,122 shares, accounting for 0.48% to 0.94% of the total share capital, to be used for employee stock ownership plans or equity incentives. The repurchase period shall be within 12 months from the date when the board of directors approves the plan. This repurchase will not have a significant impact on the company's operations, finances, etc., and will not result in a change of control. In addition, the company has highlighted the risks associated with the repurchase.